BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Garmpis N, Damaskos C, Garmpi A, Georgakopoulou VE, Sarantis P, Antoniou EA, Karamouzis MV, Nonni A, Schizas D, Diamantis E, Koustas E, Farmaki P, Syllaios A, Patsouras A, Kontzoglou K, Trakas N, Dimitroulis D. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities. J Pers Med 2021;11:223. [PMID: 33809844 DOI: 10.3390/jpm11030223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Weidong L, Sanna L, Bordoni V, Tiansheng Z, Chengxun L, Murineddu G, Pinna GA, Kelvin DJ, Bagella L. Target identification of a novel unsymmetrical 1,3,4-oxadiazole derivative with antiproliferative properties. J Cell Physiol 2021;236:3789-99. [PMID: 33089499 DOI: 10.1002/jcp.30120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Shi Y, Xiang Z, Yang H, Khan S, Li R, Zhou S, Ullah S, Zhang J, Liu B. Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma. Aging (Albany NY) 2021;13:15336-52. [PMID: 34047714 DOI: 10.18632/aging.203091] [Reference Citation Analysis]
4 Schizas D, Mastoraki A, Naar L, Tsilimigras DI, Katsaros I, Fragkiadaki V, Karachaliou GS, Arkadopoulos N, Liakakos T, Moris D. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. Curr Med Chem 2020;27:6099-111. [PMID: 31309879 DOI: 10.2174/0929867326666190712160842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
5 Mastoraki A, Schizas D, Vlachou P, Melissaridou NM, Charalampakis N, Fioretzaki R, Kole C, Savvidou O, Vassiliu P, Pikoulis E. Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma. Mol Diagn Ther 2020;24:557-69. [PMID: 32696211 DOI: 10.1007/s40291-020-00487-2] [Reference Citation Analysis]
6 Namballa HK, Anchi P, Lakshmi Manasa K, Soni JP, Godugu C, Shankaraiah N, Kamal A. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies. Bioorg Chem 2021;117:105461. [PMID: 34753060 DOI: 10.1016/j.bioorg.2021.105461] [Reference Citation Analysis]
7 Goutas D, Theocharis S, Tsourouflis G. Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia. Diagnostics (Basel) 2021;11:1346. [PMID: 34441281 DOI: 10.3390/diagnostics11081346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Huang N, Xu C, Deng L, Li X, Bian Z, Zhang Y, Long S, Chen Y, Zhen N, Li G, Sun F. PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2. Cell Death Dis. 2020;11:507. [PMID: 32632107 DOI: 10.1038/s41419-020-2708-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Xiao Y, Su M, Ou W, Wang H, Tian B, Ma J, Tang J, Wu J, Wu Z, Wang W, Zhou Y. Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer. Biomed Pharmacother 2019;117:109192. [PMID: 31387188 DOI: 10.1016/j.biopha.2019.109192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
10 Nangraj AS, Selvaraj G, Kaliamurthi S, Kaushik AC, Cho WC, Wei DQ. Integrated PPI- and WGCNA-Retrieval of Hub Gene Signatures Shared Between Barrett's Esophagus and Esophageal Adenocarcinoma. Front Pharmacol 2020;11:881. [PMID: 32903837 DOI: 10.3389/fphar.2020.00881] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
11 Huang JH, Xu Y, Lin FY. The inhibition of microRNA-326 by SP1/HDAC1 contributes to proliferation and metastasis of osteosarcoma through promoting SMO expression. J Cell Mol Med 2020;24:10876-88. [PMID: 32743904 DOI: 10.1111/jcmm.15716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Mastoraki A, Schizas D, Charalampakis N, Naar L, Ioannidi M, Tsilimigras D, Sotiropoulou M, Moris D, Vassiliu P, Felekouras E. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mol Diagn Ther 2020;24:175-84. [PMID: 32125662 DOI: 10.1007/s40291-020-00454-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Li J, Jin C, Sun L, Wang B, Hua P, Zhang Y. HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10. Clin Epigenetics 2021;13:96. [PMID: 33926524 DOI: 10.1186/s13148-021-01068-8] [Reference Citation Analysis]
14 Maslyonkina KS, Konyukova AK, Alexeeva DY, Sinelnikov MY, Mikhaleva LM. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression. Cancer Med 2021. [PMID: 34870375 DOI: 10.1002/cam4.4447] [Reference Citation Analysis]
15 Liu G, Chen H, Liu H, Zhang W, Zhou J. Emerging roles of SIRT6 in human diseases and its modulators. Med Res Rev 2021;41:1089-137. [PMID: 33325563 DOI: 10.1002/med.21753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]